- Home
- RMCF vs HIND Comparison
RMCF vs HIND Comparison
Compare RMCF & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMCF | HIND |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 28.0M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RMCF | HIND |
|---|---|---|
| Price | $2.31 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.5K | ★ 76.4K |
| Earning Date | 01-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.12 | $1.75 |
| 52 Week High | $2.99 | $12.87 |
Technical Indicators
Market Signals| Indicator | RMCF | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 30.49 |
| Support Level | $2.36 | $1.75 |
| Resistance Level | $2.60 | $2.93 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 32.35 | 0.00 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.